Morgans Senior Analyst Scott Power, and Research Analyst Iain Wilkie sneak in another episode of Under the Microscope before year-end. In this episode, the boys comment on a number of key announcements over the week and also their key picks for 2020. Featured companies include Antisense Therapeutics (ASX:ANP), Medlab Clinical (ASX: MDC), Volpara (ASX:VHT), Pro Medicus (ASX:PME), ResApp (ASX:RAP), and Opyl (ASX:OPL).
Follow some further updates on their Twitter account @MorgansHealthc1.
Listen to the full podcast here!

Dr Derek Jellinek provides feedback on Mach 7 after meeting them at a radiology conference in Chicago.

Morgans Senior Analyst Scott Power, and Research Analyst Iain Wilkie close the week with another episode of Under the microscope, the last on PODCAST for 2019. In this episode, the boys comment on key movements in the healthcare space and highlight a recent institutional placement in 1st Group (ASX:1ST). They’ve also started up a twitter account @MorgansHealthc1 so followers can keep updated.
Also a reminder of the most recent PODCAST of the series with: Michelle Gallaher from Opyl (ASX:OPL) and Tony Keating from ResApp (ASX:RAP).

Tony Keating CEO of ResApp Health outlines a number of key near-term milestones for investors to focus on.

Michelle Gallaher CEO of Opyl (ASX:OPL) explains how the company is positioning itself to growth in the digital healthcare sector.

Morgans Senior Analyst Scott Power, and Research Analyst Iain Wilkie close the week with another episode of Under the microscope. In this episode, the boys comment on key movements in the healthcare space including Iains comments on the latest in the Medical Cannabis space. Featured companies include Volpara (ASX:VHT), Pro Medicus (ASX:PME), Mach7 (ASX:M7T), Cann Group (ASX:CAN), THC Global Group (ASX:THC), Zelira Therapeutics (ASX:ZLD), Antisense Therapeutics (ASXANP) and the newly consolidated Opal Horizon (ASX:OHZ). Listen to the full podcast here!

Scott Power Morgans Senior Analyst speaks on the CSL R&D day and updates on feedback from a major radiology conference in Chicago where Volpara, Promedicus, and Mach 7 are being represented.

Morgans Senior Analyst Scott Power, closes the week with another episode of Under the microscope. In this episode, Scott comments on key movements in companies SomnoMed (ASX:SOM), Volpara Health Technologies (ASX:VHT) and Pro Medicus (ASX:PME). Listen to the full podcast here!

Matthew Liddelow, Chief Executive Officer and Managing Director of NeuroScientific Biopharmaceuticals (ASX:NSB) was interviewed by Morgans Senior Analyst Scott Power. Matthew detailed NSB as a company as well as their position heading into the next 12 months.

Morgans Senior Analyst Scott Power, and Research Analyst Iain Wilkie close the week with another episode of Under the microscope. In this episode, the boys comment on key movements within the Healthcare sector wrapping the week that was - week ending in 22 November 2019.